Reporter brief
Phase II RCT of senolytics showed safety and feasibility in older adults with mild cognitive impairment or early Alzheimer's disease
What happened
A Phase II randomized controlled trial evaluated senolytics in older adults with amnestic mild cognitive impairment or early-stage Alzheimer's disease who were tau PET positive. The study assessed safety, feasibility, and efficacy of the intervention. Specific efficacy results, sample size, and effect sizes were not reported in the available material.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Not recorded.
- Design
- Rct
- Sample
- —
- Journal
- Washington University School of Medicine
- Published
- Apr 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.